Emgality
E133653
Emgality is a prescription monoclonal antibody medication used for the prevention and treatment of migraine and cluster headaches.
All labels observed (2)
| Label | Occurrences |
|---|---|
| Emgality canonical | 2 |
| galcanezumab | 2 |
How this entity was disambiguated
This entity first appeared as the object of triple T1168577 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Emgality Context triple: [Eli Lilly and Company, notableProduct, Emgality]
-
A.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
B.
Xolair
Xolair is a monoclonal antibody medication used to treat moderate to severe allergic asthma and chronic spontaneous urticaria by targeting immunoglobulin E (IgE).
-
C.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
D.
Stelara
Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
-
E.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Emgality Target entity description: Emgality is a prescription monoclonal antibody medication used for the prevention and treatment of migraine and cluster headaches.
-
A.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
B.
Xolair
Xolair is a monoclonal antibody medication used to treat moderate to severe allergic asthma and chronic spontaneous urticaria by targeting immunoglobulin E (IgE).
-
C.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
D.
Stelara
Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
-
E.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
- F. None of above. chosen
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
calcitonin gene-related peptide inhibitor
ⓘ
medication ⓘ monoclonal antibody ⓘ |
| administrationSetting | self-administered by patient after training ⓘ |
| antibodyIsotype | IgG4 ⓘ |
| approvalBy |
European Medicines Agency
ⓘ
U.S. Food and Drug Administration ⓘ
linked to:
Food and Drug Administration
|
| bindingTargetType | peptide ligand ⓘ |
| commonAdverseEffect |
hypersensitivity reactions
ⓘ
injection site pain ⓘ injection site reactions ⓘ |
| contraindication | serious hypersensitivity to galcanezumab or excipients ⓘ |
| developedBy | Eli Lilly and Company ⓘ |
| dosageForm | subcutaneous solution ⓘ |
| EMAAuthorisationYear | 2018 ⓘ |
| FDAApprovalYear | 2018 ⓘ |
| formulation |
solution for injection in prefilled pen
ⓘ
solution for injection in prefilled syringe ⓘ |
| halfLife | approximately 27 days ⓘ |
| hasAdministrationFrequency |
more frequent dosing during cluster headache bouts
ⓘ
once monthly for migraine prevention ⓘ |
| hasATCCode | N02CD03 ⓘ |
| hasCASNumber | 1523475-53-3 ⓘ |
| hasDrugClass | CGRP monoclonal antibody ⓘ |
| hasGenericName | galcanezumab ⓘ |
| hasINN |
galcanezumab
ⓘ
linked to:
Emgality
|
| hasUNII | 6Y3J7M877I ⓘ |
| indication |
prevention of migraine in adults
ⓘ
treatment of episodic cluster headache in adults ⓘ treatment of migraine ⓘ |
| isBrandNameOf |
galcanezumab
ⓘ
linked to:
Emgality
|
| isNotIndicatedFor | acute treatment of migraine pain ⓘ |
| isPrescriptionOnly | true ⓘ |
| isUsedFor |
reducing frequency of cluster headache attacks
ⓘ
reducing frequency of migraine attacks ⓘ |
| legalStatusInEuropeanUnion | prescription only ⓘ |
| legalStatusInUnitedStates | prescription only ⓘ |
| manufacturer | Eli Lilly and Company ⓘ |
| mechanismOfAction | binds to CGRP and prevents its biological activity ⓘ |
| molecularType | humanized monoclonal antibody ⓘ |
| pregnancyCategory | use only if potential benefit justifies potential risk ⓘ |
| regulatoryDesignation | biologic medicinal product ⓘ |
| routeOfAdministration | subcutaneous injection ⓘ |
| storageCondition | refrigerated ⓘ |
| target | calcitonin gene-related peptide ⓘ |
| therapeuticArea |
headache disorders
ⓘ
neurology ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Emgality Description of subject: Emgality is a prescription monoclonal antibody medication used for the prevention and treatment of migraine and cluster headaches.
Referenced by (4)
Full triples — surface form annotated when it differs from this entity's canonical label.
linked to: Emgality
subject linked to:
Eli Lilly and Company (former executive roles prior to governorship)